Intercept Pharma (NASDAQ:ICPT) reported Q4 EPS of ($0.50), $0.07 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $77.2 million versus the consensus estimate of $78.27 million.
2023 Financial Guidance:
- Intercept is announcing 2023 Ocaliva net sales guidance of $310 million to $340 million, as compared to 2022 Ocaliva U.S. net sales of $285.7 million.
- In addition, the company is announcing 2023 non-GAAP adjusted operating expense guidance of $360 million to $390 million. See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.